Correlation Between Charles Schwab and CRISPR Therapeutics

Can any of the company-specific risk be diversified away by investing in both Charles Schwab and CRISPR Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Charles Schwab and CRISPR Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between The Charles Schwab and CRISPR Therapeutics AG, you can compare the effects of market volatilities on Charles Schwab and CRISPR Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Charles Schwab with a short position of CRISPR Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Charles Schwab and CRISPR Therapeutics.

Diversification Opportunities for Charles Schwab and CRISPR Therapeutics

0.15

Correlation Coefficient

Charles Schwab  CRISPR Therapeutics

Average diversification

The 3 months correlation between Charles and CRISPR is 0.15. Overlapping area represents the amount of risk that can be diversified away by holding The Charles Schwab and CRISPR Therapeutics AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CRISPR Therapeutics and Charles Schwab is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on The Charles Schwab are associated (or correlated) with CRISPR Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CRISPR Therapeutics has no effect on the direction of Charles Schwab i.e., Charles Schwab and CRISPR Therapeutics go up and down completely randomly.

Pair Corralation between Charles Schwab and CRISPR Therapeutics

Assuming the 90 days trading horizon The Charles Schwab is expected to generate 0.6 times more return on investment than CRISPR Therapeutics. However, The Charles Schwab is 1.68 times less risky than CRISPR Therapeutics. It trades about 0.0 of its potential returns per unit of risk. CRISPR Therapeutics AG is currently generating about -0.01 per unit of risk. If you would invest  5,787  in The Charles Schwab on December 25, 2024 and sell it today you would lose (69.00) from holding The Charles Schwab or give up 1.19% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

The Charles Schwab  vs.  CRISPR Therapeutics AG

Charles Schwab

Risk-Adjusted Performance

Very Weak

Over the last 90 days The Charles Schwab has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong technical indicators, Charles Schwab is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

CRISPR Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days CRISPR Therapeutics AG has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, CRISPR Therapeutics is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Charles Schwab and CRISPR Therapeutics

The main advantage of trading using opposite Charles Schwab and CRISPR Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Charles Schwab position performs unexpectedly, CRISPR Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CRISPR Therapeutics will offset losses from the drop in CRISPR Therapeutics' long position.

The idea behind The Charles Schwab and CRISPR Therapeutics AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.